Streamlining Dermatology Olive AI Replacement with Klivira

For dermatology practices navigating an Olive AI replacement, Klivira provides a purpose-built prior authorization automation platform designed to handle the unique complexities of skin care. Our solution ensures a smooth transition while optimizing PA workflows for biologics, specialty drugs, and procedures.

The discontinuation of Olive AI's prior authorization solution presents a critical juncture for dermatology revenue cycle and PA teams. Maintaining continuity and efficiency is paramount, especially when managing high-volume, high-cost authorizations for chronic conditions and intricate surgical procedures. Klivira offers a specialized migration path, ensuring your dermatology practice can quickly adapt and enhance its PA operations.

Navigating Dermatology Prior Authorizations Post-Olive AI

Dermatology prior authorization workflows are distinct, primarily driven by high-cost biologics for conditions like psoriasis, psoriatic arthritis, and atopic dermatitis, alongside specific surgical procedures such as Mohs micrographic surgery. Klivira's platform is engineered to address these specific PA triggers, ensuring accurate submission and adherence to payer policies for treatments like Dupixent, Cosentyx, Tremfya, Skyrizi, and Humira biosimilars, which were common PA categories managed by previous systems.

Key Dermatology PA Triggers and Documentation Requirements

Biologics for psoriasis (e.g., adalimumab, secukinumab, guselkumab, risankizumab) and atopic dermatitis (e.g., dupilumab, tralokinumab), requiring documentation of prior topical therapy trials, phototherapy trials, and conventional systemic therapy trials.
Mohs micrographic surgery, necessitating conformance with AAD Appropriate Use Criteria (AUC) based on site, tumor type, and prior treatments.
Phototherapy, distinguishing between clinic-administered and self-administered home phototherapy, often requiring prior topical therapy trials.
Advanced skin cancer treatments, including immunotherapies and targeted therapies for melanoma, which often follow NCCN guidelines.
Periodic re-authorization for chronic biologic treatments, typically on 6 or 12-month cycles, requiring ongoing disease severity documentation (PASI, EASI, BSA scores).

Addressing Common Dermatology PA Denial Patterns

Dermatology practices frequently encounter denials related to step therapy non-compliance, particularly for psoriasis biologics where failure of conventional therapies (topicals, phototherapy, methotrexate) is not adequately documented. Other common reasons include biosimilar substitution requirements for TNF inhibitors, Mohs AUC mismatches, and insufficient documentation of disease severity or pre-biologic screenings (e.g., TB, hepatitis). Klivira's rules engine is designed to proactively flag these issues before submission, aligning with AAD Clinical Guidelines and payer policies to minimize denials.

Optimizing EMR and Payer Touchpoints in Dermatology Workflows

For dermatology, efficient prior authorization hinges on seamless integration with EMR systems to extract clinical data and communicate with diverse payer channels. Klivira supports the necessary data exchange for order types related to specialty drug prescriptions and surgical procedures. Our platform facilitates the routing of authorizations based on medical versus pharmacy benefit, a critical distinction for self-injection biologics versus clinic infusions, ensuring that all relevant clinical templates and documentation are leveraged for accurate submissions.

Klivira's Approach to Dermatology Prior Authorization Automation

Klivira addresses dermatology prior authorization challenges through AAD-guideline-aware step-therapy logic for psoriasis and atopic dermatitis biologics, comprehensive AUC validation for Mohs surgery, and a robust workflow for periodic re-authorization of chronic biologic treatments. Our system accurately routes authorizations based on medical-vs-pharmacy benefit, reducing manual effort and improving turnaround times. By automating documentation collection and submission, Klivira ensures that dermatology practices can maintain continuity and enhance efficiency after an Olive AI replacement, focusing on patient care rather than administrative burdens.

Frequently asked questions

How does Klivira handle step therapy requirements for dermatology biologics?

Klivira's intelligent rules engine incorporates AAD Clinical Guidelines and payer-specific step therapy protocols for biologics used in psoriasis and atopic dermatitis. It prompts for documentation of prior topical, phototherapy, or conventional systemic therapy trials to ensure compliance before submission, reducing the likelihood of denials.

Can Klivira integrate with our existing EMR system for dermatology PA workflows?

Yes, Klivira is designed for seamless integration with major EMR systems. This allows for automated extraction of necessary clinical data, patient demographics, and order details directly from your EMR, streamlining the prior authorization process for dermatology procedures and medications.

What specific support does Klivira offer for Mohs micrographic surgery prior authorizations?

Klivira's platform includes specific logic to validate Mohs surgery prior authorizations against AAD Appropriate Use Criteria. It guides users to document critical details such as lesion site, tumor type, and prior treatments, ensuring submissions align with payer policies and reducing authorization delays.

How does Klivira manage re-authorizations for chronic dermatology conditions?

Klivira automates the tracking and initiation of re-authorization requests for chronic biologic treatments, which typically occur on 6 or 12-month cycles. The system proactively alerts your team, streamlines the collection of updated disease severity scores (PASI, EASI, BSA), and facilitates timely resubmission to prevent treatment interruptions.

Is Klivira equipped to manage both medical and pharmacy benefit prior authorizations for dermatology drugs?

Absolutely. Klivira intelligently routes prior authorizations based on whether a dermatology medication falls under the medical or pharmacy benefit. This is crucial for biologics, where self-injected drugs often fall under pharmacy benefit while clinic-administered infusions are under medical, ensuring the correct payer channel is engaged.